Key points are not available for this paper at this time.
Upon reviewing the entire pharmacoeconomic literature for six new oncology drugs, we identified differences in study reporting, but not in types of journals where studies were published, between pharmaceutical-sponsored and non-profit sponsored studies. These results, particularly the observed differences in data generalizability, may account in part for our previous finding of lower likelihood of reporting unfavorable conclusions in pharmaceutical-sponsored studies.
Fellendorf et al. (Mon,) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: